Cite
TCT-457 Paclitaxel - eluting stents vs Everolimus - eluting Coronary Stents in a Diabetic population: 2 Years Follow-up of TUXEDO-India Trial.
MLA
Kaul, Upendra, et al. “TCT-457 Paclitaxel - Eluting Stents vs Everolimus - Eluting Coronary Stents in a Diabetic Population: 2 Years Follow-up of TUXEDO-India Trial.” Journal of the American College of Cardiology (JACC), vol. 68, Nov. 2016, p. B184. EBSCOhost, https://doi.org/10.1016/j.jacc.2016.09.593.
APA
Kaul, U., Abhaichand, D. R. K., Patel, T., Banker, D., Abhyankar, A., Mullasari, A., Shah, S., Jain, R., rajendra kumar, premchand, Bahuleyan, C. G., Arambam, P., & Bangalore, S. (2016). TCT-457 Paclitaxel - eluting stents vs Everolimus - eluting Coronary Stents in a Diabetic population: 2 Years Follow-up of TUXEDO-India Trial. Journal of the American College of Cardiology (JACC), 68, B184. https://doi.org/10.1016/j.jacc.2016.09.593
Chicago
Kaul, Upendra, Dr. Rajpal K. Abhaichand, Tejas Patel, Darshan Banker, Atul Abhyankar, Ajit Mullasari, Sanjay Shah, et al. 2016. “TCT-457 Paclitaxel - Eluting Stents vs Everolimus - Eluting Coronary Stents in a Diabetic Population: 2 Years Follow-up of TUXEDO-India Trial.” Journal of the American College of Cardiology (JACC) 68 (November): B184. doi:10.1016/j.jacc.2016.09.593.